Kepler Capital Markets Analysts Give Novartis AG (NOVN) a CHF 87 Price Target

Kepler Capital Markets set a CHF 87 price objective on Novartis AG (VTX:NOVN) in a research report released on Monday morning. The brokerage currently has a buy rating on the stock.

A number of other research analysts have also issued reports on NOVN. J P Morgan Chase & Co set a CHF 70 target price on Novartis AG and gave the stock a neutral rating in a report on Saturday, May 20th. Goldman Sachs Group, Inc. (The) set a CHF 80 target price on Novartis AG and gave the stock a neutral rating in a report on Saturday, May 20th. Jefferies Group LLC set a CHF 100 target price on Novartis AG and gave the stock a buy rating in a report on Saturday, May 20th. Morgan Stanley set a CHF 75 target price on Novartis AG and gave the stock a sell rating in a report on Saturday, May 20th. Finally, Barclays PLC set a CHF 65 target price on Novartis AG and gave the stock a sell rating in a report on Friday, June 2nd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of Hold and an average target price of CHF 84.67.

Novartis AG (NOVN) opened at 79.25 on Monday. The stock has a market capitalization of CHK 185.67 billion and a P/E ratio of 28.93. Novartis AG has a 12-month low of CHK 67.40 and a 12-month high of CHK 84.35. The firm’s 50-day moving average is CHK 80.87 and its 200 day moving average is CHK 78.05.

COPYRIGHT VIOLATION WARNING: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2017/08/31/kepler-capital-markets-analysts-give-novartis-ag-novn-a-chf-87-price-target.html.

Novartis AG Company Profile

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis AG (VTX:NOVN)




Receive News & Ratings for Novartis AG Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Novartis AG and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published.

12 − five =